Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhigen Toutongan is a Traditional Chinese Medicine (TCM) capsule developed by Shandong New Era Pharmaceutical, a subsidiary of Lunan Pharmaceutical Group, for the prophylactic treatment of migraine. It is currently undergoing Phase III clinical evaluation in China (e.g., trial CTR20250990) to assess its efficacy and safety in reducing the frequency and severity of migraine attacks compared to placebo. As a botanical formulation, it likely utilizes a multi-component approach to modulate neurovascular pathways and inflammatory responses associated with migraine pathogenesis, though its specific active ingredients are typically proprietary mixtures of traditional herbs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhigen Toutongan.